Theravance Biopharma (NASDAQ:TBPH) Shares Cross Below 50 Day Moving Average of $9.04

Theravance Biopharma, Inc. (NASDAQ:TBPH)’s stock price passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $9.04 and traded as low as $8.66. Theravance Biopharma shares last traded at $8.76, with a volume of 365,377 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Evercore ISI downgraded Theravance Biopharma from an “outperform” rating to an “inline” rating in a research report on Monday, January 8th.

Theravance Biopharma Price Performance

The company has a 50-day moving average price of $9.01 and a 200-day moving average price of $9.65. The firm has a market capitalization of $434.01 million, a PE ratio of -9.29 and a beta of 0.36.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Theravance Biopharma had a negative return on equity of 19.31% and a negative net margin of 96.12%. The business had revenue of $17.57 million for the quarter, compared to analysts’ expectations of $17.49 million. On average, research analysts predict that Theravance Biopharma, Inc. will post -0.83 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Theravance Biopharma

Several large investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD increased its stake in Theravance Biopharma by 2.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 37,916 shares of the biopharmaceutical company’s stock worth $412,000 after acquiring an additional 948 shares during the last quarter. UBS Group AG increased its stake in Theravance Biopharma by 45.0% during the first quarter. UBS Group AG now owns 3,549 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 1,101 shares during the last quarter. Legal & General Group Plc increased its stake in Theravance Biopharma by 2.6% during the second quarter. Legal & General Group Plc now owns 58,904 shares of the biopharmaceutical company’s stock worth $534,000 after acquiring an additional 1,516 shares during the last quarter. Royal Bank of Canada increased its stake in Theravance Biopharma by 33.8% during the second quarter. Royal Bank of Canada now owns 6,532 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 1,649 shares during the last quarter. Finally, Principal Financial Group Inc. increased its stake in Theravance Biopharma by 10.5% during the third quarter. Principal Financial Group Inc. now owns 18,637 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 1,764 shares during the last quarter. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.